September 20th 2024
Peptides are increasingly used in cosmeceuticals for their ability to enhance cellular communication and functionality in antiaging formulations.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Reloxin effects comparable to Botox
October 21st 2005Europe's version of Botox, Dysport (Ibsen-Biotech Laboratories) is poised to officially cross the Atlantic, mainly into the offices of U.S. cosmetic surgeons, once Food and Drug Administration (FDA) approval is obtained by its U.S. marketer, Santa Barbara, Calif.-based Inamed.
Botulinum toxin popularity surges; non-cosmetic applications emerging
October 21st 2005Chicago — The popularity of botulinum toxin type A injections for correcting wrinkles of the upper face has increased dramatically over the past few years. The extent of its popularity as a cosmetic procedure is obvious when this statistic is considered: The number of botulinum toxin type A procedures rose 157 percent from 2002 to 2003; the next highest increase was chemical peels, which rose a relatively sparse 48 percent over that same period.
Combining products benefits soft tissue augmentation
October 21st 2005In Dr. Baumann's experience, Sculptra is safe and effective for off-label cosmetic use alone or in combination with other fillers. The nature of the product makes it suitable not just for filling wrinkles, but for changing the structure of the face.
Arden, Allergan team-up to market 'new' Prevage
October 4th 2005New York - In what is believed to be the first product collaboration between a cosmetics company and a drug, Elizabeth Arden Inc. and Allergan Inc., the pharmaceutical firm that markets and distributes Botox, have teamed up to market a reformulated version of Allergan's anti-aging product, Prevage.
Facial resurfacing with erbium:YAG laser
September 1st 2005New Orleans - Results of a study comparing the carbon dioxide (CO2) laser and the dual-mode long-pulsed erbium:YAG laser for ablative facial resurfacing demonstrated that patients in the erbium:YAG laser group experienced less scarring and fewer pigmentary changes, according to John L. Burns, M.D., of Dallas Plastic Surgery Institute, Dallas.
Autologous cellular treatments show long-term results with contour defects
September 1st 2005Baltimore - Results of an exploratory phase 3 clinical trial demonstrate that injection of autologous living skin fibroblasts provides safe and effective correction of facial contour deformities that is sustained for at least 12 months, reports Robert A. Weiss, M.D.
Rejuvenating the face: New trends emerge
September 1st 2005National report - Even as new techniques, devices and pharmaceutical developments for facial contouring and wrinkle refinement proliferate for dermatologists and cosmetic surgeons, two trends are gaining momentum - one for the better and one for the worse, according to dermatologist David H. McDaniel, M.D., and his colleague, cosmetic surgeon Kyle S. Choe, M.D.
Hair removal technologies expanding
September 1st 2005Chicago — As the array of laser and light sources for hair removal continues to grow, so does their efficacy and safety, according to Vic Narurkar, M.D., a dermatologist in private practice and assistant clinical professor of dermatology at the University of California, Davis, School of Medicine (and president-elect of the American Society of Cosmetic Dermatology and Aesthetic Surgery).
MAL-PDT clears Bowen's disease with excellent cosmesis
September 1st 2005National report — Photodynamic therapy using the topical photosensitizer methyl aminolevulinate 16 percent cream (Metvix, Galderma) is a non-invasive, well-tolerated, effective treatment for Bowen's disease, offering excellent cosmetic results, according to the findings of a multicenter, randomized, active- and placebo-controlled study, says Colin A. Morton, M.D., consultant dermatologist, Falkirk Royal Infirmary, Falkirk, Scotland.
New fillers finding favor in facial esthetic enhancement
September 1st 2005National report — The use of facial fillers to help counteract the effects of facial aging is becoming more widespread, with new techniques and products springing up regularly. In a recent seminar, Paul M. Friedman, M.D., comprehensively covered the topic of facial fillers, with a focus on the hyaluronic acid products.
Restraint helps avoid filler pitfalls
September 1st 2005Chicago — As physicians increasingly use injectable fillers and botulinum toxin as complementary treatments for facial rejuvenation, success depends on educating patients thoroughly and injecting products cautiously, says Seth L. Matarasso, M.D., clinical professor of dermatology at the University of California, San Francisco, School of Medicine.